AKT2 Antibody (monoclonal) (M05)
Mouse monoclonal antibody raised against a partial recombinant AKT2.
|Application ||WB, IF|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||55769 Da|
|Other Names||RAC-beta serine/threonine-protein kinase, Protein kinase Akt-2, Protein kinase B beta, PKB beta, RAC-PK-beta, AKT2|
|Target/Specificity||AKT2 (AAA58364, 100 a.a. ~ 189 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||AKT2 Antibody (monoclonal) (M05) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains. The gene was shown to be amplified and overexpressed in 2 of 8 ovarian carcinoma cell lines and 2 of 15 primary ovarian tumors. Overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins.
Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol? Rua?o G, et al. Pharmacogenomics, 2010 Jul. PMID 20602615.PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Pu X, et al. Lung Cancer, 2010 May 4. PMID 20447721.MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Foley NH, et al. Mol Cancer, 2010 Apr 21. PMID 20409325.Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. Wickenden JA, et al. Breast Cancer Res, 2010. PMID 20398329.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.